Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03608501
Other study ID # C16041
Secondary ID U1111-1214-1078
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date September 30, 2019
Est. completion date May 31, 2023

Study information

Verified date January 2020
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to determine the overall response rate (ORR) during induction therapy with the combination of ixazomib, thalidomide and low-dose dexamethasone in specific time points.


Description:

The drugs being tested in this study are a combination therapy of ixazomib, thalidomide and low-dose dexamethasone. This combination therapy is being tested to treat people who are newly diagnosed with multiple myeloma and non-eligible to autologous stem cell transplantation (ASCT). This study will assess the ORR during induction therapy in specific timepoints.

The study will enroll approximately 40 participants. All participants will receive:

Ixazomib citrate 4 mg + Thalidomide 100 mg and Dexamethasone 40 mg.

All participants will be asked to take their study medication at approximately the same time each day.

This multi-center trial will be conducted in Brazil. The overall time to participate in this study is approximately 5 years. Participants will make multiple visits to the clinic, and will be contacted by telephone or will make a final visit 30 days after receiving their last dose of drug or resolution of serious adverse event (SAE), whichever occurs later for a follow-up assessment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date May 31, 2023
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Clonal bone marrow plasma cells >=10% or biopsy-proven bony or extramedullary plasmacytoma and any one or more of the following myeloma defining events:

- Evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically:

- Hypercalcaemia: serum calcium greater than (>) 1 mg/dL higher than the upper limit of normal (ULN) or >11 mg/dL;

- Renal insufficiency: creatinine clearance <40 milliliter (mL) per minute (as per validated equations) or serum creatinine >2 mg/dL;

- Anemia: haemoglobin value of >20 gram per liter (g/L) below the lower limit of normal, or a haemoglobin value <100 g/L;

- Bone lesions: one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography (PET)-CT.

- Any one or more of the following biomarkers of malignancy:

- Clonal bone marrow plasma cell percentage >=60%.

- Involved: uninvolved serum free light chain ratio >=100.

- Greater than (>) 1 focal lesions on magnetic resonance imaging (MRI) studies. Note: clonality should be established by showing kappa to lambda ratio (?/?)-light-chain restriction on flow cytometry, immunohistochemistry, or immunofluorescence. Bone marrow plasma cell percentage should preferably be estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be used.

2. Ineligibility to autologous transplantation, as per investigator's discretion, regardless of age (the reason for such ineligibility should be recorded on the electronic case report form [eCRF]).

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

4. Ability to take concurrent aspirin daily (or enoxaparin subcutaneously daily), per published standard or institutional standard of care, as prophylactic anticoagulation.

5. Note: For participants with prior history of deep vein thrombosis (DVT), low molecular weight heparin (LMWH) is mandatory.

6. Left ventricular ejection fraction (LVEF) >=50%.

7. Clinical laboratory values as specified below within 7 days before the first dose of study drug:

- Absolute neutrophil count (ANC) >=1,500 per cubic millimeter (/mm^3), unless related to bone marrow infiltration by malignant plasma cells.

- Hemoglobin >=8.0 g/dL

- Platelet count >=75,000/mm^3, unless related to bone marrow infiltration by malignant plasma cells (platelet transfusions to help participants meet eligibility criteria are not allowed).

- Aspartate aminotransferase (AST) and alanine aminotransferase (AST) less than or equal to (<=) 1.5 times the institutional ULN.

- Bilirubin <=1.5 mg/dL (or <=2.5 mg/dL in case of Gilbert-Meulengracht syndrome).

- Glomerular filtration rate >=30 milliliter per minute per (mL/min/) 1.73 square meter (m^2) according to the Modification of Diet in Renal Disease (MDRD) study abbreviated formula. If not on target, this evaluation may be repeated once after at least 24 hours.

- Prothrombin time (PT) or activated partial thromboplastin time (aPTT) within normal limits.

Exclusion Criteria:

1. Presence of non-secretory or oligo-secretory myeloma, smoldering MM, monoclonal gammopathy of undetermined significance, plasma-cell leukemia, Waldenstrom's macroglobulinemia, primary amyloidosis, or polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome.

2. Central nervous system involvement by MM.

3. Prior radiation therapy involving an estimated >=25% of the hematopoietically active bone marrow. Radiotherapy should not be given within 14 days before enrollment. In case of palliative radiotherapy for pain control and if the involved field is small, 7 days will be considered a sufficient interval between the radiation treatment and administration of the study drugs.

4. Treatment with any investigational products within 1 (one) year before the first dose of the study drug regimen.

5. Presence of peripheral neuropathy of grade 1 with pain or grade 2 or higher.

6. Previous or concurrent history of malignancies other than MM except for curatively treated cervical carcinoma in situ, non-melanoma skin cancer, superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria]), or localized prostate cancer.

7. With evidence or history of bleeding diathesis. Any hemorrhage or bleeding event >=common terminology criteria for adverse events (CTCAE) Grade 3 within 4 weeks of start of study medication.

8. Major surgery within 14 days before randomization.

9. Non-healing wound or ulcer.

10. Seizure disorder requiring medication.

11. Systemic treatment with strong cytochrome P-450 3A (CYP3A) inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort from Day-14 of cycle 1 until the safety follow-up.

12. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ixazomib
Ixazomib capsules.
Thalidomide
Thalidomide capsules.
Dexamethasone
Dexamethasone tablets.

Locations

Country Name City State
Brazil Universidade Estadual de Campinas UNICAMP - HEMOCENTRO Campinas SP
Brazil Hospital de Clinicas de Porto Alegre Porto Alegre RS
Brazil Instituto COI de Educacao e Pesquisa Rio de Janeiro RJ
Brazil CEHON Centro de Hematologia e Oncologia da Bahia Salvador BA
Brazil Clinica Medica Sao Germano S/S Ltda. Sao Paulo SP
Brazil Hospital das Clinicas da Faculdade de Medicina da USP Sao Paulo SP

Sponsors (1)

Lead Sponsor Collaborator
Takeda

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary ORR During Induction ORR is the percentage of participants with presence of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). ORR assessment will be based on International Myeloma Working Group (IMWG) response criteria. Upon ORR assessment during specific timepoints for all participants completing or withdrawn prematurely from the induction phase (Baseline up to approximately 9 month [Cycle 9])
Secondary Progression-free Survival (PFS) PFS is the time elapsed between treatment initiation and first PD documentation or death from any cause, where PD is assessed by IMWG response criteria. Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 2 years])
Secondary ORR During Maintenance ORR is the percentage of participants with presence of sCR, CR, VGPR or PR. ORR assessment will be based on IMWG response criteria. Upon ORR assessment during specific time points for all participants completing or withdrawn prematurely from maintenance phase (Baseline up to approximately 2 years)
Secondary Overall Survival (OS) OS is defined as the time elapsed between treatment initiation and death from any cause. Upon study termination (Baseline up to approximately 5 years)
Secondary Time to Response During Induction Time to response is the time elapsed between treatment initiation and the first documentation of sCR, VGPR or PR according to the IMWG response criteria. End of induction phase (Baseline up to approximately 9 months [Cycle 9])
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1
Recruiting NCT04111809 - Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care